Sex-Specific Association Between Genetic Risk of Psychiatric Disorders and

Cardiovascular Diseases

Jiayue-Clara Jiang (PhD)[1*], Kritika Singh (BA)[2,3*], Lea K. Davis (PhD)[2,3,4,5,6], Naomi R. Wray
(PhD)[1,7], Sonia Shah (PhD)[1]

[1] Institute for Molecular Bioscience, The University of Queensland, St Lucia, 4072, Australia

[2] Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[3] Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

[4] Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[5] Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[6] Departments of Medicine and Biomedical Informatics, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[7] Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK

*co-first authors

Short title: The brain-heart disease link greater in women

Corresponding authors:

Sonia Shah, PhD

Email: s.shah1@uq.edu.au

Address: 306 Carmody Rd, Institute for Molecular Bioscience, The University of Queensland, St
Lucia, Australia, 4072

Jiayue-Clara Jiang, PhD

Email: j.jiang@uq.edu.au

Address: 306 Carmody Rd, Institute for Molecular Bioscience, The University of Queensland, St
Lucia, Australia, 4072

The total word count of the manuscript (including Title Page, Abstract, Text, References, Tables
and Figures Legends): 8914

Abstract

Background

The lack of research on female-specific risk factors for cardiovascular diseases (CVD) has led to

sex-based disparities in cardiovascular health. Though epidemiological studies show increased

CVD risks amongst individuals with psychiatric disorders, findings on sex differences in

comorbidity have been inconsistent.

Methods

This genetic epidemiology study examined the sex-specific association between the genetic risk

of three psychiatric disorders [major depression (MD), schizophrenia and bipolar disorder],

estimated using polygenic scores (PGS), and risks of three CVDs [atrial fibrillation (AF), coronary

artery disease (CAD) and heart failure (HF)] in 345,169 European-ancestry individuals (UK

Biobank), with analyses replicated in an independent BioVU cohort (N=49,057). Mediation

analysis was conducted to determine whether traditional CVD risk factors could explain any

observed sex difference.

Results

In UK Biobank, PGS_{MD} was significantly associated with the incident risks of all three CVDs in

females after multiple testing correction [hazard ratio $(HR)_{AF\text{-}female}$=1.04 (95% CI: 1.02-1.06;

p=0.00015); $HR_{CAD\text{-}female}$=1.07 (1.04-1.11; p=2.6E-06); $HR_{HF\text{-}female}$=1.09 (1.06-1.13; p=9.7E-10)],

but not in males. These female-specific associations remained even in the absence of any

psychiatric disorder diagnosis or psychiatric medication use. Although mediation analysis

demonstrated that the association between PGS_{MD} and CVDs in females was partly mediated by

baseline BMI, hypercholesterolemia, hypertension and smoking, these risk factors did not explain the higher risk compared to males. The association between PGS_{MD} and CAD was consistent between females who were pre-menopausal and post-menopausal at baseline (mean baseline age of 44.9 and 60.8 years, respectively), while the association with AF and HF was only observed in the baseline post-menopausal cohort. No significant association with CVD risks was observed for the PGS of schizophrenia or bipolar disorder. The positive association of PGS_{MD} with CAD and HF risk in females was replicated in BioVU, where the corresponding associations in males also reached nominal significance.

Conclusions

Genetic predisposition to MD confers a greater risk of CVDs in females versus males, even in the absence of any depression diagnosis. This study warrants further investigation into whether genetic predisposition to depression could be useful for improving cardiovascular risk prediction even in the absence of a depression diagnosis, especially in women.

Keywords

psychiatric disorder; cardiovascular disease; depression; polygenic score; sex-specific risks; menopause

1   Non-Standard Abbreviations and Acronyms

Abbreviation	Definition
AF	Atrial fibrillation
AHA	American Heart Association
BD	Bipolar disorder
BMI	Body mass index
CAD	Coronary artery disease
CI	Confidence interval
CPT	Current Procedural Terminology
CVD	Cardiovascular disease
EHR	Electronic health record
GWAS	Genome-wide association study
HF	Heart failure
HR	Hazard ratio
ICD	International Classification of Diseases
LD	Linkage disequilibrium
MD	Major depression
MR	Mendelian randomisation
OR	Odds ratio
PC	Principal component
PGS	Polygenic score
PRS-CS	Polygenic Risk Score–Continuous Shrinkage
SCZ	Schizophrenia
SD	Standard deviation
SNP	Single nucleotide polymorphism
T2D	Type II diabetes
VUMC	Vanderbilt University Medical Center

Introduction

The idea that mental health is linked to cardiovascular health has long been recognised: William Harvey wrote in 1628 "every affection of the mind that is attended with either pain or pleasure, hope or fear, is the cause of an agitation whose influence extends to the heart" [1]. Modern epidemiological studies find that collectively, individuals with psychiatric disorders, namely major depression (MD), schizophrenia (SCZ) and bipolar disorder (BD), have a ~50% higher odds of developing cardiovascular diseases (CVD) [2]. The increased CVD risk amongst individuals with psychiatric disorders may be attributed to a combination of genetic and non-genetic factors, with the latter including the use of prescribed psychiatric medications [3] and the adoption of adverse habits, such as smoking and social isolation [4].

There is marked sex difference in both the prevalence and clinical presentation of psychiatric disorders. Depression is twice as prevalent in females than males (lifetime prevalence of 26.1% versus 14.7%) [5], with women showing augmented symptom severity [6]. While the prevalence of SCZ does not differ between sexes, some studies have found that men show a higher incidence (incidence risk ratio = 1.42), earlier age of onset and worse premorbid functioning [7]. Men also show an earlier onset for BD, although the prevalence is reported to be equal between sexes for bipolar I disorder but higher in women for bipolar II disorder, which is characterised by depressive episodes [8]. Despite a higher lifetime risk of CVD in men (60.3% versus 55.6% in women at an index age of 45 years) [9], CVD is a leading cause of female deaths [10], and yet CVD risk in women remains underappreciated and under-researched, leading to under-diagnosis and under-treatment of CVDs in women [10].

Few studies have investigated the sex differences in the cardiovascular comorbidity of SCZ and BD, and observational studies have presented inconsistent findings on the sex-specific association between depression and CVD outcomes [11]. While some observational studies (N≤3,237) have found depression or depressive symptoms to be a risk factor for heart failure (HF) and coronary artery disease (CAD) amongst women but not in men [12,13], a study on a Chinese cohort (N=512,712) found an association between depression and CVD-related mortality in men only [14]. The variability in findings may be due to differences in sample sizes, unmeasured confounders, follow-up times, sex balance in the cohort, and the criteria for defining depression phenotypes and CVD outcomes. At the same time, observational studies cannot establish causal associations and cannot determine if this risk is a direct result of medication, which are known to have an adverse cardiometabolic effect [3], or other environmental factors in consequence of a diagnosis of depression. Furthermore, although an association between depressive symptoms and increased CAD risk in women aged ≤ 55 years (but not in women aged > 55 years) was previously observed [13], it remains unknown how the menopause transition (perimenopause), a period where adverse changes in body composition, lipids, and measures of vascular health occur [15], affects the cardiovascular comorbidity amongst women with a higher risk of depression.

Large genome-wide association studies (GWAS) have been very successful at identifying genetic loci associated with disease risk. Novel statistical methods applied to GWAS data are facilitating our understanding of shared biology between diseases, as well as in making causal inferences in disease comorbidity, overcoming some of the caveats of observational studies. Previous genetic analyses, for example, have used Mendelian randomisation (MR) to provide evidence to support a causal effect of depression on CAD and HF [16]. However, few studies have investigated sex differences using such genetic approaches, with an example being a small-scale study (N=18,385,

50.9% female) that showed a positive association between MD and CAD in females but not males

[17]. To what extent genetic factors contribute to comorbidity between psychiatric disorders and

CVDs in different sexes is an outstanding question, and one that will better inform CVD prevention

strategies. In this study, we used polygenic scores (PGS) derived from GWAS summary statistics

(which estimate an individual's genetic liability to a disease) to examine the sex-specific

association between a higher genetic risk of three psychiatric disorders [BD, MD and SCZ] and

the risk of three CVDs [atrial fibrillation (AF), CAD and HF] in the UK Biobank cohort of over

345,000 individuals. The findings were independently replicated in a BioVU cohort of over 49,000

individuals.

Methods

UK Biobank cohort summary

The UK Biobank cohort consists of over 500,000 participants (aged 40-69 years at baseline) from

the UK, who were recruited between 2006 and 2010 [18]. Diverse phenotypic and genomic data were

collected from participants, such as clinical diagnosis, physical and biochemical measurements,

and answers from questionnaires. Consent was collected from all participants. The current study

was conducted using the UK Biobank Resource under Application Number 12505. This research

is covered by The University of Queensland Human Research Ethics Committee approval (HREC

number 2020/HE002938).

Using information provided by the UK Biobank genotype data release, quality control was

performed to remove individuals who were outliers for heterozygosity and genotype missing rates,

who were excluded from kinship inference, who showed evidence of putative sex chromosome

aneuploidy, and who showed mismatching self-reported and genetically inferred sex (definitions

of exclusion criteria are described in Bycroft et al. [18]). Individuals who have withdrawn from the

study or have missing phenotypes [baseline body mass index (BMI) or smoking status] were

excluded from the analysis. After quality control, a total of 345,169 unrelated (genetic relatedness

< 0.05) individuals of European ancestry (inferred from the genetic data) were subjected to analysis

in this study (ancestry calling is described in Yengo et al. [19]).

BioVU cohort summary

Vanderbilt University Medical Center (VUMC) is a tertiary care centre that provides inpatient and

outpatient care in middle Tennessee, US. The VUMC electronic health record (EHR) system,

established in 1990, includes data on billing codes from the International Classification of Diseases

9th and 10th editions (ICD-9 and ICD-10), Current Procedural Terminology (CPT) codes,

laboratory values, reports, and clinical documentation. In 2007, VUMC launched a biobank,

BioVU, which links a patient's DNA sample to their EHR. The BioVU consent form is provided

to patients in the outpatient clinic environments at VUMC. The VUMC Institutional Review Board

oversees BioVU and approved this project (IRB#172020). At VUMC, all medical record data were

extracted from the EHRs of 72,634 individuals of European ancestry, determined by genetic

ancestry analysis. To reduce missingness of clinical data and enrich the sample for patients who

receive their primary care at VUMC, our analysis included only individuals who met the "medical

home" definition, requiring the presence of any five codes on different days over a period of at

least three years. We further excluded individuals who did not have a BMI measurement or age

recorded in the EHRs, leaving a total of 49,057 individuals for analysis.

UK Biobank phenotype ascertainment

UK Biobank phenotypic data collected between 2006 and March 2023 was used for phenotype

extraction. Detailed inclusion and exclusion criteria of all disease phenotypes in the UK Biobank

are provided in Supplementary Methods, Supplementary Table 1 and Supplementary Table 2.

For each CVD, prevalent cases consisted of individuals who had disease-associated phenotypes

recorded at baseline or after recruitment into UK Biobank, defined using self-reported illnesses

(data-field 20002), self-reported operation codes (data-field 20004), operative procedures

(OPCS4) (data-field 41272), ICD-9 diagnoses (data-field 41271), ICD-10 diagnoses (data-field

41270) and primary (data-field 40001) or contributory (data-field 40002) death causes (not all

criteria were used for all phenotype definitions). Incident cases were defined as individuals who

did not self-report any disease-associated illness or operation code at initial assessment

[determined using data-field 53 ("Date of attending assessment centre"), data-field 20008

("Interpolated Year when non-cancer illness first diagnosed") and data-field 20010 ("Interpolated

Year when operation took place")], and did not have any disease-associated OPCS4 procedure or

diagnosis (ICD-9 or ICD-10) prior to or at the time of initial assessment [determined using data-

field 41282 ("Date of first operative procedure - OPCS4"), data-field 41281 ("Date of first in-

patient diagnosis - ICD-9") and data-field 41280 ("Date of first in-patient diagnosis - ICD-10")].

For prevalent cases who answered "Date uncertain or unknown" or "Preferred not to answer" to

data-fields 20008 and 20010, the corresponding self-reported illness diagnosis or operation date

was set to be the date on which they attended the assessment centre when they self-reported the

illness or operation (data-field 53). The process of defining prevalent and incident cases is

presented in Figure 1.

For the mediation analysis, the baseline status of the disease risk factors of CVDs

[hypercholesterolemia, hypertension, and type II diabetes (T2D)] was defined using criteria in

Supplementary Table 1. Incident cases of these risk factors, defined as described above, were removed from the mediation analysis.

Smoking status at baseline (whether a person has smoked ever, defined as current or previous smokers) was collated from UK Biobank data-field 20116 ("Smoking status"). The baseline BMI of individuals was retrieved from data-field 21001 ["Body mass index (BMI)"]. The ages at baseline (in years) of individuals were calculated using "Date of attending assessment centre" (data-field 53) and "Year of birth" (data-field 34). Summary of characteristics for the whole cohort and the cohort with no psychiatric diagnosis and medications are shown in Table 1 and Supplementary Table 3 respectively.

BioVU phenotype ascertainment

For the BioVU cohort, we defined phenotypes based on Phecodes, which are higher-order combinations of at least two related ICD codes, occurring on two different days, using the R PheWAS package [20] (detailed Phecodes are shown in Supplementary Table 4). Smoking status was ascertained by "tobacco use disorder" (Phecode 318). The median BMI and median age of individuals were selected from assessments taken at chronological visits, available in the medical records at VUMC. Summary of characteristics is presented in Supplementary Table 5.

GWAS summary statistics

Association summary statistics derived from European-ancestry or predominantly European-ancestry cohorts were retrieved for three CVDs (AF, CAD and HF) and three psychiatric disorders (BD, MD and SCZ), and were used for generating PGS in the UK Biobank and BioVU cohorts (datasets summarised Supplementary Table 6). To avoid discovery bias, GWAS summary statistics

used for single nucleotide polymorphism (SNP) selection and per-allele weight estimation were

derived from studies that did not include individuals from the corresponding target cohorts (UK

Biobank or BioVU).

Polygenic score generation

PGS is an estimate of the lifetime genetic liability of an individual to a trait. Briefly, we define a

PGS of an individual, j, as a weighted sum of SNP allele counts: $\sum_{i=1}^{m} \hat{b}_i x_{ij}$, where m is the number

of SNPs included in the predictor, $\hat{b}_i$ is the per-allele weight (based on the estimated effect of the

allele on trait value) for the SNP, x_{ij} is a count of the number (0, 1, or 2) of trait-associated alleles

of SNP i in individual j.

Several methods are available for optimising the choice of SNPs and the per-allele weights for

PGS calculation. For analysis in the UK Biobank cohort, we used SBayesR [21] which implements

a Bayesian approach to model genetic architecture, is computationally efficient, and does not

require a training dataset for identifying trait-associated SNPs and estimating per-allele weights

[21,22]. A linkage disequilibrium (LD) reference dataset was downloaded from the SBayesR website

(banded LD matrix) and default settings were used unless otherwise stated (--exclude-mhc; --

chain-length 50000; --burn-in 10000; --no-mcmc-bin) [21]. For each disease, we applied PLINK1.9

[23] to calculate the PGSs (based on SbayesR SNPs and weights) in UK Biobank individuals. For

BioVU, PGSs were generated using Polygenic Risk Score–Continuous Shrinkage (PRS-CS) [24]

(which has been shown to have similar performance to SbayesR [22]). The LD reference panel was

constructed from 503 European samples in the 1000 Genomes Project Phase 3.41.

The PGS distribution was scaled to a mean of zero and standard deviation (SD) of 1; therefore,

effect size estimates in subsequent regression analyses were interpreted as changes in outcome per

1-SD increase in PGS. We generated PGS for 345,169 unrelated, European-ancestry individuals

[186,683 (54.1%) females and 158,486 (45.9%) males] from the UK Biobank, and 49,057

individuals [28,094 (57.3%) females and 20,963 (42.7%) males] from BioVU. To validate the

PGS, logistic regression was used to examine the association with disease prevalent cases in the

prediction cohort (UK Biobank or BioVU) (Supplementary Table 7). PGS performance was

evaluated using the Nagelkerke pseudo R^2 [R package "rcompanion" [25] (version 2.4.13)]. The

Nagelkerke pseudo R^2 compares the reduced model [for UK Biobank: containing only sex, BMI,

smoking status, genotyping array, age at baseline and 20 genetic principal components (PC) as

predictors; for BioVU: containing only sex, BMI, smoking status, age and 10 genetic PCs as

predictors] and the full model (with PGS added as a predictor), and is a relative measure of how

well the full model explains the data compared to the reduced model. Overall, the addition of PGSs

improved the prediction performance in our study, as indicated by positive Nagelkerke R^2 values

(Supplementary Table 7). Our models demonstrate comparable performance to the corresponding

PGSs generated previously using different methods [24,26-28] (Supplementary Table 7).

Cox proportional hazards regression analysis

In UK Biobank, for each psychiatric-CVD disorder pair, we performed age-as-time-scale Cox

proportional hazards regression to investigate the sex-specific association between psychiatric

disorder PGS and incident CVD. For each CVD incident case, we defined their time-to-event as

the number of months since birth [estimated using "Year of birth" (data-field 34) and "Month of

birth" (data-field 52)], to the age they were diagnosed with CVD [estimated using "Date of first

in-patient diagnosis" (data-field 41280)], first self-reported CVD illness [estimated using

"Interpolated Year when non-cancer illness first diagnosed" (data-field 20008)], self-reported

operation codes [estimated using "Interpolated Year when operation took place" (data-field

20010)], had the CVD-associated OPCS4 procedures [estimated using "Date of first operative procedure - OPCS4" (data-field 41282)] or died of CVDs [estimated using "Date of death" (data-field 40000)]. If an individual met multiple disease-associated criteria (such as having had both a disease-associated ICD-10 diagnosis and OPCS4 procedure), their time-to-event was defined as the earliest time at which they met any disease-associated criteria.

We censored CVD controls at the age of death, age of losing contact [estimated using "Date lost to follow-up" (data-field 191)], or age at censoring (March 2023). The Cox models included BMI, smoking status, genotyping array and 20 genetic PCs as covariates, and were analysed using the "Survival" package (version 3.2.11) in R [29]. A $p<0.0028$ was chosen to indicate statistical significance (multiple testing correction for 18 tests – association of three psychiatric PGS with three CVDs in two sexes). The regression coefficients (beta) for the PGS were compared between sexes using a Wald test (statistical significance declared at two-sided $p<0.05$). Given previously reported genetic correlations between CVD and depression [30], to assess if the MD PGS were associated with CVD risks independently of the CVD PGS, we performed a sensitivity analysis where the PGS for the relevant CVD was fitted as an additional covariate. Due to the bidirectional relationships amongst the different CVDs, we performed a further sensitivity analysis where the PGSs for all CVDs were fitted as additional covariates. For all subsequent subgroup analyses, a nominal significance threshold ($p<0.05$) was applied due to the reduction in sample sizes.

Cox proportional hazards analysis in females stratified by baseline menopausal status

We sought to determine if the association between genetic risk of MD and risk of incident CVD differed between two groups of women at different stages of menopause at baseline. Menopause status at baseline was determined using UK Biobank data-field 2724 ("Had menopause?"). We

first explored the MD-CVD association amongst females who were post-menopausal at baseline

(who answered "yes" to the survey question "Had menopause?" at the initial assessment visit).

The mean age of natural menopause is 50 years (interquartile range = 48.0–53.0 years) [15], we thus

also conducted analysis in a cohort consisting of females who at baseline were less than 50 years

of age and pre-menopausal (answered "no" to "Had menopause?" at the initial assessment), and

either answered "no" or did not answer the "Had menopause" question in subsequent assessments

(about 18.7% of females who answered "no" to "Had menopause?" at the initial assessment

completed at least one follow-up assessment on menopausal status). Females who at baseline did

not answer, answered "preferred not to answer", or answered "not sure" to the menopause question

were excluded from both menopausal groups, while those who in any follow-up assessments

reported to have had menopause, answered "preferred not to answer", or answered "not sure" were

also excluded from the baseline pre-menopausal group.

A total of 141,709 females in the study met the criteria for either menopausal group, including

114,375 (80.7%) females who self-reported to have had menopause at baseline, and 27,334

(19.3%) females in the baseline pre-menopausal group. We performed Cox proportional hazards

regression analysis (as described above) between PGS_{MD} and incident CVDs in the two

menopausal groups. BMI, smoking status, genotyping array, and 20 genetic PCs were included in

the model as covariates. For each CVD, we applied a Wald test to compare the Cox regression

coefficient (beta) for PGS_{MD} in each menopausal group against the previously estimated

coefficient in males.

Mediation analysis with CVD-associated risk factors

To explore whether the association between the genetic risk of MD and incident CVDs can be explained by a CVD-associated risk factor, sex-stratified mediation analysis was performed using the "mediation" R package (version 4.5.0) [31]. Five risk factors (baseline BMI, hypercholesterolemia status at baseline, hypertension status at baseline, smoking status at baseline and T2D status at baseline) were modelled as mediators between PGS_{MD} (exposure) and incident CVD (outcome). The mediation models included baseline BMI (except in the analysis of baseline BMI as the mediator), baseline smoking status (except in the analysis of smoking status as the mediator), age at baseline, genotyping array and 20 genetic PCs as covariates. Each mediation analysis was performed with 10,000 bootstrap simulations to estimate the variance and significance of the mediation, and statistical significance was defined by $p < 0.0017$ (multiple testing correction for three CVDs, five risk factors and two sexes).

Association between the genetic risk of MD and CVD in individuals with no diagnosis of psychiatric disorders or psychiatric medication use

To dissociate the effects of behavioural changes or medication use as a consequence of depression diagnosis, sex-stratified Cox proportional hazards regression analysis was performed between PGS_{MD} and incident CVD risks amongst UK Biobank participants who did not meet the criteria for the three psychiatric disorders, had no ICD diagnosis of personality or neurotic disorders, had no self-reported history of mood disorders, and were not on any antidepressants or antipsychotic medications (detailed phenotype information in Supplementary Table 2). A total of 286,162 individuals from the UK Biobank cohort met the above criteria and were included for analysis.

Logistic regression in BioVU

Findings from UK Biobank were tested for association in the independent BioVU cohort at

VUMC. Based on methods used in previous BioVU studies [17], logistic regression was used to

estimate the sex-stratified association of psychiatric disorder PGS with prevalent CVDs, including

median age, median BMI, smoking status and 10 genetic PCs as covariates. In a sensitivity

analysis, we additionally adjusted for the presence of a Phecode for any of the psychiatric

conditions (BD, MD, SCZ, personality disorders, mood disorders, or anxiety, dissociative and

somatoform disorders) (Supplementary Table 4), along with the presence of antidepressant use,

defined as whether a person has ever used an antidepressant. Statistical significance was declared

at $p<0.05$.

Results

Increased genetic risk of MD is associated with a greater increase of AF, CAD and HF risk

in females

Sex-stratified Cox proportional hazards regression analysis showed that after multiple testing

correction ($p<0.0028$), a 1-SD increase in PGS_{MD} was significantly associated with increased risks

of all three CVDs in females [hazard ratio $(HR)_{AF-female}$ = 1.04 (95% CI: 1.02 - 1.06; p=0.00015);

$HR_{CAD-female}$ = 1.07 (95% CI: 1.04 - 1.11; p=2.6E-06); $HR_{HF-female}$ = 1.09 (95% CI: 1.06 - 1.13;

p=9.7E-10)], but not in males, and the association with incident CAD and HF was significantly

higher in females compared to males (two-sided Wald test p=0.016 and 0.00032 respectively)

(Figure 2). These associations remained even after correcting for the genetic risks of all three

CVDs (Supplementary Figure 1), indicating that PGS_{MD} captured additional risk for CVD over

and above that captured by the PGSs for all three CVDs. No associations between PGS for SCZ

or BD with CVD risks passed multiple testing correction in either sex (Figure 2).

Menopausal status influences the association between genetic risk of MD and incident CVDs

We further explored the association between PGS_{MD} and incident CVDs in females stratified by their baseline menopausal status. As expected from previous evidence on the increase in CVD risks after menopause [15], the incidence of CVD was higher in the post-menopausal group (6.1%, 2.9% and 3.1% for AF, CAD and HF, respectively), compared to the pre-menopausal group (0.8%, 0.7% and 0.5% for AF, CAD and HF, respectively) (chi square p<2E-16) (Supplementary Table 8). Using a nominal significance (p<0.05) threshold, we found that PGS_{MD} was significantly associated with increased incident CAD regardless of baseline menopausal status [$HR_{CAD-pre}$ = 1.22 (95% CI: 1.06 - 1.42; p=0.0063); $HR_{CAD-post}$ = 1.07 (95% CI: 1.03 - 1.11; p=0.00012)]. The associations with CAD risk in both the baseline pre- and post-menopausal female groups were higher than in males (two-sided Wald test p=0.019 and 0.047, respectively) (Figure 3). A 1-SD increase in PGS_{MD} was also associated with incident AF and HF in the baseline post-menopausal females [$HR_{AF-post}$ = 1.03 (95% CI: 1.01 - 1.06; p=0.0064); $HR_{HF-post}$ = 1.10 (95% CI: 1.06 - 1.13; p=8.2E-08)], and the association with incident HF was significantly higher than the male cohort (two-sided Wald test p=0.00089). Despite risk estimates that were higher than or similar to those observed in the post-menopausal cohort, the associations between PGS_{MD} with incident AF or HF in the baseline pre-menopausal group were not statistically significant [HR_{AF-pre} = 1.07 (95% CI: 0.94 – 1.23; p=0.29; HR_{HF-pre} = 1.10 (95% CI: 0.92 – 1.30; p=0.30)], which may be a reflection of the much smaller sample size for the pre-menopausal cohort (Figure 3).

The associations between the genetic risk of MD and CVDs are partly mediated by BMI, hypercholesterolemia, hypertension and smoking

To gain a mechanistic insight into the association between PGS_{MD} and CVD risk, we performed a sex-stratified mediation analysis to investigate whether traditional modifiable CVD risk factors could explain the observed sex difference. Although the association between PGS_{MD} and CVD risk in females was found to be partly mediated by a number of traditional risk factors (namely BMI, hypercholesterolemia, hypertension and smoking), given that the proportion of CVD risk explained by each of the risk factors was higher in males (though not all statistically significant after multiple testing correction), the observed higher risk in females is unlikely to be explained by these traditional risk factors (Table 2). For example, baseline BMI mediates 34% (95%CI: 21% - 78%; p=0.00060) of the association between PGS_{MD} and incident AF in males, but only 25% (95% CI: 18% - 41%; p<2E-16) in females (Table 2).

Genetic risk of MD is associated with increased CVD risk in females even in the absence of psychiatric diagnosis or psychiatric medication use

Amongst individuals who had no psychiatric disorder diagnosis and were not on any psychiatric medication (N=286,162), we observed a nominally positive association of PGS_{MD} with incident AF [$HR_{AF\text{-}female}$ = 1.03 (95% CI: 1.01 - 1.06; p=0.013)], incident CAD [$HR_{CAD\text{-}female}$ = 1.04 (95% CI: 1.01 - 1.08; p=0.016)] and incident HF [$HR_{HF\text{-}female}$ = 1.07 (95% CI: 1.04 – 1.11; p=0.00012)] in females only (Figure 4).

Replication of main findings in the BioVU cohort

We repeated our analysis in the independent BioVU cohort (N=49,057). Similar to the UK Biobank cohort, using a nominal significance threshold (p<0.05), we observed a positive association of PGS_{MD} with prevalent CAD in both sexes of the BioVU cohort [odds ratio ($OR_{CAD\text{-}female}$) = 1.08 (95% CI: 1.03 – 1.12; p=0.00043) and $OR_{CAD\text{-}male}$ = 1.04 (95% CI: 1.00 – 1.08;

p=0.044)] (Supplementary Figure 2). However for HF, we observed a positive association in not

only females [$OR_{HF\text{-}female}$ = 1.07 (95% CI: 1.02 – 1.11; p=0.0036)], but also in males [$OR_{HF\text{-}male}$ =

1.06 (95% CI: 1.02 – 1.10; p=0.0072)], with no significant difference in risk between the two sexes

(two-sided Wald test p > 0.05) (Supplementary Figure 2). Unlike the UK Biobank, we did not

observe an association between PGS_{MD} and AF in either sex. Interestingly, we observed a negative

association of both PGS_{BD} and PGS_{SCZ} with prevalent CAD and HF in the males of BioVU, which

may be suggestive of survivial bias (Supplementary Figure 2). A nominally significant genetic

associations of PGS_{MD} with HF in both sexes, and with CAD in females was observed in the

sensitivity analyses adjusting for the diagnosis of psychiatric disorders and antidepressant

medication use (Supplementary Figure 3).

Discussion

Using data from the UK Biobank cohort, we show for the first time the association between genetic

predisposition to MD with incident AF and HF in females but not in males, and validate a

previously reported sex difference (increased risk in women) in the association with CAD. As we

observed a larger number of CVD cases in males and therefore had greater power to detect a risk

estimate equivalent to that found in females, the observed sex difference in the depression-CVD

associations was unlikely to be driven by differences in statistical power. We also show for the

first time that the genetic risk of depression is associated with increased risks of CVDs even in the

absence of psychiatric diagnosis or psychiatric medication use, and this association is thus not

simply a consequence of behavioural changes or medication following a depression diagnosis.

Interestingly, the association with incident CAD was consistent amongst females who were pre-

menopausal at baseline (average age of 44.9 years at baseline) as well as in older females who

were post-menopausal at baseline (mean age of 60.8 years at baseline), while the increased risk of

incident AF and HF was only observed in the latter group. Our results from mediation analysis

suggest that although the depression-CVD link is partly mediated by traditional CVD risk factors,

these do not explain the sex difference observed in UK Biobank. Additional risk factors need to

be investigated to understand the driver of the higher CVD risks in women.

We repeated these analyses in the independent BioVU cohort, which was limited by its much

smaller sample size, potential ascertainment bias (data only available on individuals who were

admitted to VUMC) and potential survival bias (incident data unavailable). We were able to

replicate the association between the genetic risk of MD and increased HF and CAD risks in

females, though both associations were also significant in males of BioVU, possibly due to the

aforementioned limitations.

A few observational studies have found depression to be associated with increased AF, CAD and

HF risk in women, and such associations were either weaker or absent in men [12,13,32]. However,

observational studies are prone to unmeasured confounder bias and reverse causation. These

studies also have not been able to determine if this risk is independent of psychiatric medication

use. Previous genetic analyses that utilise GWAS summary data to assess causality have shown

that an increased genetic risk for MD is associated with an increased CAD and HF risk [16].

However, these studies lacked a sex perspective, except for a previously reported genetic

association between MD PGS and CAD observed in females but not males in a (smaller) BioVU

cohort [17].

In this study, we observed comparable risk estimates between PGS_{MD} and incident CVDs amongst

two cohorts of women who were at different menopausal stages at enrolment into the UK Biobank,

although the risk estimates in the pre-menopausal cohort were restricted by sample size and thus

did not reach statistical significance for AF and HF. The menopause transition involves extensive

changes in sex hormones, body composition, and lipid profiles, which can increase CVD risk in

women post-menopause [15]. Our findings demonstrate that depression may be an important

consideration in CVD risk assessment regardless of menopausal stage.

Mediation analyses suggest that the higher CVD risk associated with higher genetic predisposition

to MD in females versus males is not explained by traditional CVD risk factors. Possible

mechanisms underlying the sex difference in the comorbidity of depression and CVDs include

hormonal dysregulation and pro-inflammatory responses. Specific subtypes of depression, such as

postpartum depression and post-menopausal depression, suggest the involvement of hormone

fluctuations in depression amongst females [33]. Interestingly, Takotsubo cardiomyopathy, often

triggered by emotional or physical stress, is more common in post-menopausal women (90% of

cases) [34]. At the same time, elevated inflammatory biomarkers, such as interleukin-6 and tumour

necrosis factor alpha, are reportedly higher in depressed women relative to depressed men,

suggesting a sex-differential inflammatory response to MD [33]. These pro-inflammatory cytokines

are linked to CVD risks [35]. Further studies are required to understand the role of these factors in

the heightened risk of CVDs amongst females with depression.

Currently, QRISK3 prediction algorithm (UK) is the only CVD risk prediction calculator that

incorporates diagnoses of severe mental illnesses as risk factors for primary prevention [36]. In New

Zealand, individuals with severe mental illness are advised to undergo earlier and more frequent

risk assessments [37]. In Australia, severe mental illnesses are recommended as a 'reclassification

factor' and to be used to refine CVD risk categorisation for individuals whose risk predicted from

traditional risk factors lies close to a threshold of a higher-risk group [38]. Furthermore, the American

Heart Association (AHA) has recommended incorporation of a depression diagnosis as a risk

factor of adverse prognosis amongst patients with acute coronary syndrome [39], but the diagnosis of depression is not currently incorporated into the calculation of CVD risk (Pooled Cohort Equations) in US [40]. Given the observation of higher CVD risk in individuals who are genetically predisposed to depression, even in the absence of a depression diagnosis, future studies investigating any benefit of including such information in risk tools is warranted, especially in women.

The strengths of our study lie, firstly, in the investigation of sex-specific psychiatric-CVD comorbidity, and the ability to dissociate the effects of depression from medications and behaviour changes following diagnosis. However, limitations of our study need to be acknowledged. We derived PGSs from sex-combined summary statistics of GWAS, which might fail to capture genetic variants that confer sex-differential associations. The between-sex genetic correlations for BD, MD and SCZ are reported to range between 0.86 and 1, indicating moderate to subtle sex differences in the genetic architecture of these psychiatric disorders [41]. Nevertheless, PGSs derived from sufficiently powered sex-stratified GWAS studies, which are becoming increasingly available for neuropsychiatric and cardiovascular traits [41,42], will provide additional information on the sex-differential genetic factors in diseases. Moreover, due to the lower number of CVD cases amongst females in UK Biobank, our analysis in the female cohort had lower power. In addition, the analysis of CVD risk difference between different menopausal states did not account for the potential effects of any menopause treatments which are known to impact CVD risks [43]. Over 47.5% (54,350 out of 114,375) of baseline post-menopausal females in this study self-reported having used hormone replacement therapy at baseline (versus only 1.5% of the baseline pre-menopausal cohort). This is an important consideration for future studies to dissociate the effects of such treatments on the CVD risk amongst individuals with a genetic predisposition of

MD. Furthermore, the "healthy-volunteer bias" in UK Biobank is well documented, where

individuals with severe mental illnesses are underrepresented compared to the general population

[44]. While an underrepresentation of depression is also present in this cohort, it is estimated that this

bias is likely more prominent for more several mental illnesses, namely schizophrenia [44].

To our best knowledge, this is the first study that has explored sex-specific association between

the genetic risk of three different psychiatric disorders and risks of AF, CAD and HF, with further

stratification for menopause status. Given that these CVDs have both shared and unique underlying

disease biology, future research into the shared and unique biological pathways through which

increased risk of depression increases the risk of different CVDs may be important for informing

prevention strategies. CVD risk calculators that do not incorporate psychiatric disorders as a

predictor are reported to underestimate CVD risk by 30% and 60% in men and women respectively

[45]. Our results warrant further investigation into the predictive value of depression risk in CVD

risk calculators, even in the absence of a depression diagnosis, as well as further studies on how

AF, CAD and HF risk differs across different menopausal stages.

Acknowledgments

We would like to thank the research participants and employees of 23andMe, inc. for making this work possible. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data.

The dataset(s) used for the BioVU analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/. This publication (journal article, etc.) was supported by Grant No. R01 HG011405, partially funded by the Office of Research on Women's Health, Office of the Director, NIH and the National Human Genome Research Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Office of Research on Women's Health or the National Human Genome Research Institute.

The scripts used in the study are available on: https://github.com/CNSGenomics/CVD_psych_PRS_Jiang.

Sources of Funding

JCJ is supported by a National Health and Medical Research Council (NHMRC) IDEAS grant

(2000637). KS is supported by the American Heart Association Predoctoral Fellowship

(AHA827137). LKD is supported by funding from the National Institute of Mental Health (NIMH)

(R56MH120736); and the National Human Genome Research Institute (NHGRI) and the Office

of Research on Women's Health (R01HG011405). NRW is supported by NHMRC Program Grant

(1113400); and NHMRC Investigator Grant (1173790). SS is supported by funding from the

NHMRC Program Grant (1113400); NHMRC Early Career Fellowship (APP1142495); and

National Heart Foundation Future Leader Fellowship (105638).

Disclosures

None.

References

1.   Graboys TB. Stress and the aching heart. *N Engl J Med*. 1984;311:594-595.

2.   Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. *World Psychiatry*. 2017;16:163-180.

3.   Marano G, Traversi G, Romagnoli E, Catalano V, Lotrionte M, Abbate A, Biondi-Zoccai G, Mazza M. Cardiologic side effects of psychotropic drugs. *J Geriatr Cardiol*. 2011;8:243-253.

4.   Larsen BA, Christenfeld NJS. Cardiovascular disease and psychiatric comorbidity: the potential role of perseverative cognition. *Cardiovasc Psychiatry Neurol*. 2009;2009:791017-791017.

5.   Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. *JAMA Psychiatry*. 2018;75:336-346.

6.   Marcus SM, Kerber KB, Rush AJ, Wisniewski SR, Nierenberg A, Balasubramani GK, Ritz L, Kornstein S, Young EA, Trivedi MH. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. *Compr Psychiatry*. 2008;49:238-246.

7.   Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. *Schizophr Res Treatment*. 2012;2012:916198.

8.   Vega P, Barbeito S, de Azúa SR, Martínez-Cengotitabengoa M, González–Ortega I, Saenz

M, González-Pinto A. Bipolar disorder differences between genders: special

considerations for women. *Womens Health*. 2011;7:663-676.

9.   Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and years

lived free of total cardiovascular disease. *JAMA*. 2012;308:1795-1801.

10.   Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero M,

Kunadian V, Lam CSP, Maas AHEM, et al. The Lancet women and cardiovascular disease

Commission: reducing the global burden by 2030. *The Lancet*. 2021;397:2385-2438.

11.   Möller-Leimkühler AM. Gender differences in cardiovascular disease and comorbid

depression. *Dialogues Clin Neurosci*. 2007;9:71-83.

12.   Williams SA, Kasl SV, Heiat A, Abramson JL, Krumholz HM, Vaccarino V. Depression

and risk of heart failure among the elderly: a prospective community-based study.

Psychosom Med. 2002;64:6-12.

13.   Shah AJ, Ghasemzadeh N, Zaragoza-Macias E, Patel R, Eapen DJ, Neeland IJ, Pimple PM,

Zafari AM, Quyyumi AA, Vaccarino V. Sex and age differences in the association of

depression with obstructive coronary artery disease and adverse cardiovascular events. *J*

Am Heart Assoc. 2014;3:e000741.

14.   Meng R, Yu C, Liu N, He M, Lv J, Guo Y, Bian Z, Yang L, Chen Y, Zhang X, et al.

Association of depression with all-cause and cardiovascular disease mortality among adults

in China. *JAMA Network Open*. 2020;3:e1921043-e1921043.

15.   Khoudary SRE, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher

MC, Manson JE, Stefanick ML, Allison MA. Menopause transition and cardiovascular

disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. *Circulation*. 2020;142:e506-e532.

16. Lu Y, Wang Z, Georgakis MK, Lin H, Zheng L. Genetic liability to depression and risk of coronary artery disease, myocardial infarction, and other cardiovascular outcomes. *J Am Heart Assoc*. 2021;10:e017986.

17. Dennis J, Sealock J, Levinson RT, Farber-Eger E, Franco J, Fong S, Straub P, Hucks D, Song WL, Linton MF, et al. Genetic risk for major depressive disorder and loneliness in sex-specific associations with coronary artery disease. *Mol Psychiatry*. 2021;26:4254-4264.

18. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203-209.

19. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling TM, Hirschhorn J, Yang J, Visscher PM, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry. *Hum Mol Genet*. 2018;27:3641-3649.

20. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. *Bioinformatics*. 2014;30:2375-2376.

21. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, Wang H, Zheng Z, Magi R, Esko T, et al. Improved polygenic prediction by Bayesian multiple regression on summary statistics. *Nat Commun*. 2019;10:5086.

22.   Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, Restuadi R, Kiewa J, Nyholt DR,
Coleman JRI, et al. A comparison of ten polygenic score methods for psychiatric disorders
applied across multiple cohorts. *Biol Psychiatry*. 2021;90:611-620.

23.   Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation
PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015;4:s13742-
13015-10047-13748.

24.   Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian
regression and continuous shrinkage priors. *Nat Commun*. 2019;10:1776.

25.   Mangiafico S. rcompanion: Functions to support extension education program evaluation.
In; 2022.

26.   Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander
ES, Lubitz SA, Ellinor PT, et al. Genome-wide polygenic scores for common diseases
identify individuals with risk equivalent to monogenic mutations. *Nat Genet*.
2018;50:1219-1224.

27.   Wang Y, Namba S, Lopera E, Kerminen S, Tsuo K, Läll K, Kanai M, Zhou W, Wu K-H,
Favé M-J, et al. Global Biobank analyses provide lessons for developing polygenic risk
scores across diverse cohorts. *Cell Genomics*. 2023;3:100241.

28.   Reginsson GW, Ingason A, Euesden J, Bjornsdottir G, Olafsson S, Sigurdsson E,
Oskarsson H, Tyrfingsson T, Runarsdottir V, Hansdottir I, et al. Polygenic risk scores for
schizophrenia and bipolar disorder associate with addiction. *Addict Biol*. 2018;23:485-492.

29.   Therneau TM. A Package for Survival Analysis in R. R package version 3.5-7,
https://CRAN.R-project.org/package=survival. In; 2023.

30.   Zhang F, Cao H, Baranova A. Shared genetic liability and causal associations between

major depressive disorder and cardiovascular diseases. *Front Cardiovasc Med*. 2021;8.

31.   Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R package for causal

mediation analysis. *Journal of Statistical Software*. 2014;59:1 - 38.

32.   Kim YG, Lee K-N, Han K-D, Han K-M, Min K, Choi HY, Choi YY, Shim J, Choi J-I,

Kim Y-H. Association of depression with atrial fibrillation in South Korean adults. *JAMA*

Network Open. 2022;5:e2141772-e2141772.

33.   Tobaldini E, Carandina A, Toschi-Dias E, Erba L, Furlan L, Sgoifo A, Montano N.

Depression and cardiovascular autonomic control: a matter of vagus and sex paradox.

Neurosci Biobehav Rev. 2020;116:154-161.

34.   Schneider B, Sechtem U. Influence of age and gender in Takotsubo Syndrome. *Heart Fail*

Clin. 2016;12:521-530.

35.   Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di

Angelantonio E, Gudnason V, Rumley A, Lowe GDO, et al. Inflammatory cytokines and

risk of coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart*

J. 2014;35:578-589.

36.   Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk

prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort

study. *BMJ*. 2017;357:j2099.

37.   Ministry of Health New Zealand. Cardiovascular disease risk assessment and management

for primary care. 2018.

38.   Commonwealth of Australia as represented by the Department of Health and Aged Care.

Australian Guideline for assessing and managing cardiovascular disease risk. 2023.

39.   Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N,

Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, et al. Depression as a risk factor

for poor prognosis among patients with acute coronary syndrome: systematic review and

recommendations. *Circulation*. 2014;129:1350-1369.

40.   Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de

Ferranti   S,   Faiella-Tommasino   J,   Forman   DE,   et   al.   2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA

guideline on the management of blood cholesterol: a report of the American College of

Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2019;139:e1082-e1143.

41.   Martin J, Khramtsova EA, Goleva SB, Blokland GAM, Traglia M, Walters RK, Hübel C,

Coleman JRI, Breen G, Børglum AD, et al. Examining sex-differentiated genetic effects

across neuropsychiatric and behavioral traits. *Biol Psychiatry*. 2021;89:1127-1137.

42.   Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E,

Saleheen D, Erdmann J, Goldstein BA, et al. Large-scale association analysis identifies

new risk loci for coronary artery disease. *Nat Genet*. 2013;45:25-33.

43.   Boardman HMP, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel

Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-

menopausal women. *Cochrane Database of Systematic Reviews*. 2015.

44.   Schoeler T, Speed D, Porcu E, Pirastu N, Pingault J-B, Kutalik Z. Participation bias in the

UK Biobank distorts genetic associations and downstream analyses. *Nature Human*

Behaviour. 2023;7:1216-1227.

45.   Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of

cardiovascular disease risk among people with severe mental illness: A cohort study. *PLoS*

One. 2019;14:e0221521-e0221521.

2   Table 1. Summary of characteristics of the UK Biobank cohort

		Female		Male	
	Total Number	186683		158486	
	Average age at baseline in years (SD)	57 (7.9)		57.4 (8.1)	
	Average BMI at baseline (SD)	26.9 (5.1)		27.8 (4.2)	
	Current or previous smokers at baseline (%)	77180 (41.3)		81209 (51.2)	
		Case	Control*	Case	Control*
Prevalent BD	N (%)	817 (0.4)	148856 (79.7)	585 (0.4)	137306 (86.6)
	Age at baseline (SD)	56.1 (7.9)	57 (7.9)	57.4 (7.9)	57.4 (8.1)
Prevalent MD	N (%)	12774 (6.8)	148856 (79.7)	7316 (4.6)	137306 (86.6)
	Age at baseline (SD)	57 (8)	57 (7.9)	57.5 (8.1)	57.4 (8.1)
Prevalent SCZ	N (%)	654 (0.4)	148856 (79.7)	733 (0.5)	137306 (86.6)
	Age at baseline (SD)	57 (8.4)	57 (7.9)	56.5 (8.5)	57.4 (8.1)
Incident AF	N (%)	8926 (4.8)	176132 (94.3)	14180 (8.9)	140403 (88.6)
	Age at baseline (SD)	62.6 (5.9)	56.7 (7.9)	62.2 (6.2)	56.8 (8.1)
Incident CAD	N (%)	4451 (2.4)	180294 (96.6)	10160 (6.4)	140167 (88.4)
	Age at baseline (SD)	61.4 (6.5)	56.8 (7.9)	60.4 (6.9)	56.9 (8.1)
Incident HF	N (%)	4644 (2.5)	181392 (97.2)	7653 (4.8)	149136 (94.1)
	Age at baseline (SD)	62.7 (6.1)	56.8 (7.9)	62.4 (6.2)	57.1 (8.1)
Hypercholesterolemia status at baseline	N (%)	19799 (10.6)	148376 (79.5)	27753 (17.5)	105053 (66.3)
	Age at baseline (SD)	61.8 (5.9)	55.9 (7.9)	61.4 (6.4)	55.6 (8.2)
Hypertension status at baseline	N (%)	43831 (23.5)	122590 (65.7)	49984 (31.5)	85607 (54)
	Age at baseline (SD)	60.3 (6.8)	55.4 (7.9)	60.3 (7)	55.2 (8.2)
T2D status at baseline	N (%)	2638 (1.4)	175375 (93.9)	4637 (2.9)	141330 (89.2)
	Age at baseline (SD)	60.6 (6.9)	56.8 (7.9)	61.6 (6.3)	57 (8.1)
	Baseline post-menopausal (%)**	114375 (80.7)		-	
	Baseline pre-menopausal (%)**	27334 (19.3)		-	

* Controls for BD, MD and SCZ were individuals who had no diagnosis of psychiatric disorders or psychiatric
medication use. For each CVD, individuals with the CVD at baseline were removed from the incident analysis, and
individuals who developed CVD after enrolment into UK Biobank were removed from baseline analysis.
** Menopausal status was defined by self-reported menopausal status at baseline (baseline post-menopausal: females
who answered "yes" to having had menopause at baseline; baseline pre-menopausal: females who answered "no" to
having had menopause at baseline). Female participants who met any of the following criteria were excluded from the
pre-menopausal group: 1) females who did not report to have had menopause at baseline but later self-reported
menopause in follow-up assessments (although only ~18.7% of females who did not report to have had menopause at
baseline completed follow-up surveys on their menopausal status); 2) females who did not report to have had
menopause at baseline but were at least 50 years of age at baseline; 3) females who preferred not to answer or self-
reported to be not sure about their menopausal status at baseline or any follow-up assessment. The percentages shown
in the table represent percentages of total females who met the criteria for either menopausal group (N=141,709).
15

Table 2. Sex-stratified mediation analysis of risk factors modelled as mediators of the association between PGS_{MD} and incident CVDs in UK Biobank. Mediation effects that passed multiple testing correction (p<0.0017) are highlighted in bold.

Outcome	Mediator	Sex	Prop. Mediated (average)	95% CI Lower	95% CI Upper	P
Incident AF	Baseline BMI	Female	**0.25**	**0.18**	**0.41**	**< 2E-16**
		Male	**0.34**	**0.21**	**0.78**	**0.0006**
	Baseline hypercholesterolemia	Female	**0.085**	**0.038**	**0.25**	**0.0006**
		Male	0.13	0.043	0.43	0.0086
	Baseline hypertension	Female	**0.17**	**0.088**	**0.35**	**< 2E-16**
		Male	0.46	0.21	2.5	0.027
	Baseline smoking status	Female	**0.089**	**0.059**	**0.19**	**< 2E-16**
		Male	0.18	0.093	0.59	0.0062
	Baseline T2D	Female	0.021	0.0072	0.08	0.012
		Male	0.075	0.019	0.36	0.024
Incident CAD	Baseline BMI	Female	**0.13**	**0.094**	**0.21**	**< 2E-16**
		Male	0.24	0.14	0.74	0.0064
	Baseline hypercholesterolemia	Female	**0.098**	**0.048**	**0.24**	**0.0004**
		Male	0.16	0.042	0.69	0.02
	Baseline hypertension	Female	**0.14**	**0.081**	**0.34**	**0.0002**
		Male	0.44	0.18	1.5	0.016
	Baseline smoking status	Female	**0.098**	**0.071**	**0.18**	**< 2E-16**
		Male	0.22	0.11	0.69	0.0074
	Baseline T2D	Female	0.043	0.012	0.11	0.015
		Male	0.072	-0.018	0.39	0.09
Incident HF	Baseline BMI	Female	**0.17**	**0.13**	**0.24**	**< 2E-16**
		Male	0.39	0.23	1.2	0.0034
	Baseline hypercholesterolemia	Female	**0.084**	**0.038**	**0.17**	**0.0006**
		Male	0.15	0.069	0.7	0.014
	Baseline hypertension	Female	**0.16**	**0.073**	**0.25**	**< 2E-16**
		Male	0.37	0.19	1.3	0.0078
	Baseline smoking status	Female	**0.099**	**0.063**	**0.14**	**< 2E-16**
		Male	0.31	0.15	1.1	0.016
	Baseline T2D	Female	0.057	0.013	0.11	0.013
		Male	0.22	-0.77	1.6	0.079

1   **Figures with Figure Legends**

2
3   Figure 1. Flow chart for defining prevalent and incident CVD cases in the UK Biobank cohort.
4   *The full inclusion and exclusion criteria for each disease are presented in Supplementary Table
5   1.

1
Figure 2. Age-specific change in risk of incident CVDs per SD increase in psychiatric disorder
PGSs in the UK Biobank cohort. Associations for the sex-stratified cohorts (red - female; blue -
male) were estimated with Cox proportional hazards regression models. X-axis shows the HR per
SD increase in PGS, with p-values labelled, and error bars indicate 95% confidence intervals.
Asterisk (*) indicates a statistically significant difference in the beta values between females and
males (two-sided Wald test p<0.05). Dark grey line indicates HR of 1. AF, atrial fibrillation; BD,
bipolar disorder; CAD, coronary artery disease; HF, heart failure; HR, hazard ratio; MD, major
depression; PGS, polygenic score; SCZ, schizophrenia; SD, standard deviation.

1
Figure 3. Age-specific change in risk of incident CVDs per SD increase in PGS_{MD} in the UK
Biobank cohort, stratified by menopausal status. Associations for females who were baseline post-
menopausal (orange) and baseline pre-menopausal (pink) were estimated with Cox proportional
hazards regression models, and the estimates for the male cohort (blue) are shown for the purpose
of comparison. X-axis shows the HR per SD increase in PGS, with p-values labelled, and error
bars indicate 95% confidence intervals. Asterisk (*) indicates a statistically significant difference
(two-sided Wald test $p<0.05$) in the beta values between the corresponding female cohort and male
cohort. Dark grey line indicates HR of 1. AF, atrial fibrillation; CAD, coronary artery disease; HF,
heart failure; HR, hazard ratio; MD, major depression; PGS, polygenic score; SD, standard
deviation.

1
Figure 4. Age-specific change in risk of incident CVDs per SD increase in PGS$_{MD}$ amongst UK
Biobank individuals with no diagnosis of psychiatric disorders and psychiatric medications.
Associations for the sex-stratified cohorts (red - female; blue - male) were estimated with Cox
proportional hazards regression models. X-axis shows the HR per SD increase in PGS, with p-
values labelled, and error bars indicate 95% confidence intervals. Asterisk (*) indicates a
statistically significant difference in the beta values between females and males (two-sided Wald
test p<0.05). Dark grey line indicates HR of 1. AF, atrial fibrillation; CAD, coronary artery disease;
HF, heart failure; HR, hazard ratio; MD, major depression; PGS, polygenic score; SD, standard
deviation.

1   **Supplementary Material**

2   of

3   **Sex-Specific Association Between Genetic Risk of Psychiatric Disorders and**

4   **Cardiovascular Diseases**

Jiayue-Clara Jiang (PhD)[1*], Kritika Singh (BA)[2,3*], Lea K. Davis (PhD)[2,3,4,5,6], Naomi R. Wray

(PhD)[1,7], Sonia Shah (PhD)[1]

[1] Institute for Molecular Bioscience, The University of Queensland, St Lucia, 4072, Australia

[2] Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[3] Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

[4] Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[5] Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[6] Departments of Medicine and Biomedical Informatics, Vanderbilt University Medical Center,
Nashville, TN, 37232, USA

[7] Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK

*co first authors

Supplementary Methods

CVD and risk factor phenotype ascertainment in UK Biobank

AF cases were defined by the presence of self-reported atrial fibrillation or atrial flutter, self-

reported cardioversion operation, ICD-10 (I48, I48.0-4, I48.9) or ICD-9 (4273) billing codes

indicative of atrial fibrillation or atrial flutter, OPCS4 procedures (K57.1, K62.1-4), or death

causes indicative of atrial fibrillation or atrial flutter (same as the ICD-10 codes).

CAD cases were ascertained based on myocardial infarction or coronary revascularisation.

Myocardial infarction was defined by self-reported heart attack/myocardial infarction, or ICD-10

(I21.X, I22.X, I23.X, I24.1, I25.2) or ICD-9 (4109, 4119, 4129) billing codes for myocardial

infarction. Coronary revascularisation was defined by OPCS4 codes for coronary artery bypass

grafting (K40.1–4, K41.1–4, or K45.1–5) or coronary angioplasty with or without stenting (K49.1–

2, K49.8–9, K50.2, K75.1–4, K75.8–9).

HF cases were ascertained by the presence of self-reported heart failure/pulmonary odema or

cardiomyopathy, ICD-10 (I11.0, I13.0, I13.2, I25.5, I42.0, I42.5, I42.8, I42.9, I50.0, I50.1, I50.9)

or ICD-9 (4254, 4280, 4281, 4289) billing codes indicative of heart/ventricular failure or

cardiomyopathy, or death causes indicative of heart/ventricular failure or cardiomyopathy.

Individuals with hypertrophic cardiomyopathy, defined by self-reported illness, ICD-10 (I42.1,

I42.2) billing codes, ICD-9 (4251) billing codes or death causes, were excluded from the HF

analyses.

Hypercholesterolemia cases were defined by self-reported high cholesterol, ICD-10 (E780) or

ICD-9 (27200, 27209) codes for hypercholesterolemia, or death causes indicative of

hypercholesterolemia. Individuals who were not defined as a hypercholesterolemia case, but self-reported to be on cholesterol-lowering medication were removed from the hypercholesterolemia controls.

Hypertension cases were defined by self-reported hypertension, ICD-10 (I10) or ICD-9 (4010, 4011, 4019) codes for essential (primary) hypertension, or death causes indicative of hypertension. Individuals who were not defined as a hypertension case but self-reported to be taking blood pressure medications were removed from the hypertension controls.

T2D cases were defined by self-reported T2D, ICD-10 (E11.X) or ICD-9 (25000, 25010) codes for non-insulin-dependent diabetes mellitus, or death causes indicative of T2D. Individuals who were not defined as a hypertension case but had Type I diabetes or were taking insulin were removed from the T2D controls. Type I diabetes cases were defined by self-reported, ICD-10 (E10.X) codes, ICD-9 (25001, 25011) codes, or death causes.

Psychiatric phenotype definitions in UK Biobank

BD cases were ascertained by the presence of ICD-10 (F30.0, F30.1, F30.2, F30.8, F30.9, F31.X) or ICD-9 (2960, 2961, 2969) codes for manic episode or bipolar affective disorder. SCZ cases were defined using ICD-10 (F20.X, F21.X, F22.X, F23.X, F24.X, F25.X, F28.X, F29.X) or ICD-9 (2953, 2959) codes for schizophrenia, schizotypal and delusional disorders. MD cases were defined by ICD-10 (F32.X, F33.X, F34.X, F38.X, F39.X) or ICD-9 (3119, 2962) codes for depressive episode, recurrent depressive disorder, persistent mood (affective) disorders, other mood (affective) disorders or unknown mood (affective) disorders. Individuals were removed from the MD cases if they were a case for BD or SCZ, had self-reported schizophrenia (1289), had an ICD-10 code of multiple personality disorder (F44.8), or were taking antipsychotics. The controls

1   for BD, SCZ and MD were individuals who had no diagnosis of psychiatric disorders and were

2   not taking any psychiatric medication (see definitions in Methods).

Supplementary Figures

Supplementary Figure 1. Sensitivity analyses on the association between PGS_{MD} and incident CVDs, performed on the UK Biobank cohort, where the corresponding CVD PGS or all three CVD PGSs (AF, CAD and HF) were added as covariates to the model. Associations for the sex-stratified cohorts (red - female; blue - male) were estimated with Cox proportional hazards regression models. X-axis shows the HR per SD increase in PGS, with p-values labelled, and error bars indicate 95% confidence intervals. Asterisk (*) indicates a statistically significant difference in the beta values between females and males (two-sided Wald test $p<0.05$). Dark grey line indicates HR of 1. AF, atrial fibrillation; CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; MD, major depression; PGS, polygenic score; SD, standard deviation.

1
Supplementary Figure 2. Association between psychiatric disorder PGSs and prevalent CVDs in
the BioVU cohort. Associations for the sex-stratified cohorts (red - female; blue - male) were
estimated with logistic regression. X-axis shows the OR per SD increase in PGS, with p-values
labelled, and error bars indicate 95% confidence intervals. Asterisk (*) indicates a statistically
significant difference in the beta values between females and males (two-sided Wald test p<0.05).
Dark grey line indicates OR of 1. AF, atrial fibrillation; BD, bipolar disorder; CAD, coronary
artery disease; HF, heart failure; MD, major depression; OR, odds ratio; PGS, polygenic score;
SCZ, schizophrenia; SD, standard deviation.

Supplementary Figure 3. Association between PGS$_{MD}$ and prevalent CVDs amongst individuals
of the BioVU cohort, where the status of psychiatric disorders and antidepressant were added as
covariates to the model. OR was estimated with logistic regression. X-axis shows the OR per SD
increase in PGS, with p-values labelled, and error bars indicate 95% confidence intervals. Dark
grey line indicates OR of 1. AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure;
MD, major depression; OR, odds ratio; PGS, polygenic score; SD, standard deviation.

1 Supplementary Tables

2 Supplementary Table 1. UK Biobank CVD and associated risk factors phenotype ascertainment criteria

Disease	Criteria	Data field	Data field description	Codes
AF	Inclusion	20002	Non-cancer illness code, self-reported	1471, 1483
		20004	Operation code	1524
		41270	ICD-10	I48, I480, I481, I482, I483, I484, I489
		41271	ICD-9	4273
		41272	Operative procedures - OPCS4	K571, K621, K622, K623, K624
		40001 and 40002	Primary and secondary causes of death	I48, I480, I481, I482, I483, I484, I489
CAD	Inclusion	20002	Non-cancer illness code, self-reported	1075
		41270	ICD-10	I210, I211, I212, I213, I214, I219, I220, I221, I228, I229, I230, I231, I232, I233, I235, I236, I238, I241, I252
		41271	ICD-9	4109, 4119, 4129
		41272	Operative procedures - OPCS4	K401, K402, K403, K404, K411, K412, K413, K414, K451, K452, K453, K454, K455, K491, K492, K498, K499, K502, K751, K752, K753, K754, K758, K759
		40001 and 40002	Primary and secondary causes of death	I210, I211, I212, I213, I214, I219, I220, I221, I228, I229, I230, I231, I232, I233, I235, I236, I238, I241, I252
HF	Inclusion	20002	Non-cancer illness code, self-reported	1076, 1079
		41270	ICD-10	I110, I130, I132, I255, I420, I425, I428, I429, I500, I501, I509
		41271	ICD-9	4254, 4280, 4281, 4289
		40001 and 40002	Primary and secondary causes of death	I110, I130, I132, I255, I420, I425, I428, I429, I500, I501, I509
	Exclusion	20002	Non-cancer illness code, self-reported	1588
		41270	ICD-10	I421, I422
		41271	ICD-9	4251
		40001 and 40002	Primary and secondary causes of death	I421, I422
Hyper-cholesterolemia	Inclusion for cases	20002	Non-cancer illness code, self-reported	1473
		41270	ICD-10	E780
		41271	ICD-9	27200, 27209
		40001 and 40002	Primary and secondary causes of death	E780
	Exclusion from controls	6177	Medication for cholesterol, blood pressure or diabetes	1 (Cholesterol lowering medication)
		6153	Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	1 (Cholesterol lowering medication)
Hypertension	Inclusion for cases	20002	Non-cancer illness code, self-reported	1065, 1072
		41270	ICD-10	I10
		41271	ICD-9	4010, 4011, 4019
		40001 and 40002	Primary and secondary causes of death	I10
	Exclusion from controls	6177	Medication for cholesterol, blood pressure or diabetes	2 (Blood pressure medication)
		6153	Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	2 (Blood pressure medication)
T2D	Inclusion for cases	20002	Non-cancer illness code, self-reported	1223
		41270	ICD-10	E110, E111, E112, E113, E114, E115, E116, E117, E118, E119
		41271	ICD-9	25000, 25010
		40001 and 40002	Primary and secondary causes of death	E110, E111, E112, E113, E114, E115, E116, E117, E118, E119
	Exclusion from controls	20002	Non-cancer illness code, self-reported	1222
		41270	ICD-10	E100, E101, E102, E103, E104, E105, E106, E107, E108, E109
		41271	ICD-9	25001, 25011
		6177	Medication for cholesterol, blood pressure or diabetes	3 (Insulin)
		6153	Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	3 (Insulin)
		40001 and 40002	Primary and secondary causes of death	E100, E101, E102, E103, E104, E105, E106, E107, E108, E109

1 Supplementary Table 2. UK Biobank psychiatric disorder phenotype ascertainment criteria

Disease	Criteria	Data field	Data field description	Codes
BD	Inclusion	41270	ICD-10	F300, F301, F302, F308, F309, F310, F311, F312, F313, F314, F315, F316, F317, F318, F319
		41271	ICD-9	2960, 2961, 2969
SCZ	Inclusion	41270	ICD-10	F200, F201, F202, F203, F204, F205, F206, F208, F209, F21, F220, F228, F229, F230, F231, F232, F233, F238, F239, F24, F250, F251, F252, F258, F259, F28, F29
		41271	ICD-9	2953, 2959
MD	Inclusion	41270	ICD-10	F320, F321, F322, F323, F328, F329, F330, F331, F332, F333, F334, F338, F339, F340, F341, F348, F349, F380, F381, F388, F39
		41271	ICD-9	3119, 2962
	Exclusion	BD cases SCZ cases 41270	ICD-10	F448
		20002	Non-cancer illness code, self-reported	1289
		20003	Treatment/medication code	Antipsychotics: 1141202024, 1141153490, 1141195974, 1140867078, 1140867494, 1141171566, 2038459704, 1140872064, 1140879658, 1140867342, 1140867420, 1140882320, 1140872216, 1140910358, 1141200458, 1141172838, 1140867306, 1140867180, 1140872200, 1140867210, 1140867398, 1140882098, 1140867184, 1140867168, 1140863416, 1140909802, 1140867498, 1140867490, 1140910976, 1140867118, 1140867456, 1140928916, 1140872268, 1140867134, 1140867208, 1140867218, 1140867572, 1140879674, 1140909804, 1140867504, 1140868170, 1140879746, 1141152848, 1141177762, 1140867444, 1140867092, 1141152860, 1140872198, 1140867244, 1140868172, 1140867304, 1140872072, 1140879750, 1140868120, 1140872214, 1141201792, 1140882100, 1141167976
No diagnosis /medication	Exclusion from full cohort	BD cases MD cases SCZ cases 41270	ICD-10	F21, F29, F419, F410, F411, F418, F449, F444, F446, F440, F441, F448, F681, F688, F409, F400, F401, F402, F408, F341, F488, F489, F99, F601, F604, F607, F609
		41271	ICD-9	3000, 3001, 3002, 3004, 3005, 3009, 3012, 3015, 3016, 3019
		20002	Non-cancer illness code, self-reported	1286, 1287, 1288, 1289, 1290, 1291, 1531
		20003	Treatment/medication code	Antipsychotics (see above) Antidepressants: 1140867820, 1140867948, 1140879616, 1140867938, 1140867690, 1141190158, 1141151946, 1140921600, 1140879620, 1141201834, 1140867152, 1140909806, 1140879628, 1140867640, 1141200564, 1141151982, 1140916288, 1141180212, 1140867860, 1140867952, 1140879540, 1140867150, 1140909800, 1140867940, 1140879544, 1140879630, 1140867856, 1140867726, 1140867884, 1140867922, 1140910820, 1140879556, 1141152732, 1140867920, 1140882244, 1140867852, 1140867818, 1141174756, 1140867916, 1140867888, 1140867850, 1140867624, 1140867876, 1141151978, 1140882236, 1140867878, 1201, 1140882312, 1140867758, 1140867712, 1140867914, 1140867944, 1140879634, 1140867756, 1140867934, 1140867960, 1140916282, 1141200570, 1141152736

Supplementary Table 3. Summary of characteristics of participants in the UK Biobank cohort who had no diagnosis of psychiatric disorders and were not on any antidepressants or antipsychotics

		Female		Male	
Total Number		148856		137306	
Average age at baseline in years (SD)		57 (7.9)		57.4 (8.1)	
Average BMI at baseline (SD)		26.7 (4.9)		27.7 (4.1)	
Current or previous smokers at baseline (%)		59328 (39.9)		68777 (50.1)	
		Case	Control	Case	Control
Incident AF	N (%)	6375 (4.3)	141290 (94.9)	11643 (8.5)	122363 (89.1)
	Age at baseline (SD)	62.7 (5.8)	56.7 (7.9)	62.3 (6.1)	56.8 (8.1)
Incident CAD	N (%)	3039 (2)	144506 (97.1)	8365 (6.1)	122328 (89.1)
	Age at baseline (SD)	61.9 (6.2)	56.9 (7.9)	60.6 (6.9)	56.9 (8.1)
Incident HF	N (%)	2958 (2)	145465 (97.7)	5938 (4.3)	130027 (94.7)
	Age at baseline (SD)	63.2 (5.7)	56.9 (7.9)	62.7 (6.1)	57.1 (8.1)
Hypercholesterolemia status at baseline	N (%)	14309 (9.6)	121454 (81.6)	22797 (16.6)	93255 (67.9)
	Age at baseline (SD)	62.1 (5.7)	56 (7.9)	61.6 (6.3)	55.7 (8.2)
Hypertension status at baseline	N (%)	32739 (22)	101591 (68.2)	41542 (30.3)	76756 (55.9)
	Age at baseline (SD)	60.6 (6.7)	55.4 (7.9)	60.5 (6.9)	55.2 (8.2)
T2D status at baseline	N (%)	1694 (1.1)	141370 (95)	3556 (2.6)	123883 (90.2)
	Age at baseline (SD)	61.3 (6.6)	56.8 (7.9)	61.9 (6.1)	57.1 (8.2)

Supplementary Table 4. BioVU phenotype ascertainment criteria

Disease	Phecodes
AF	427.2
CAD	411.4
HF	428, 428.1, 428.2, 428.3, 428.4
BD	296.1
MD	296.2, 296.22
SCZ	295.1
Anxiety, dissociative and somatoform disorders	300
Personality disorders	301
Mood disorders	296

Supplementary Table 5. Summary of characteristics in the BioVU cohort

		Female		Male	
Total Number		28094		20963	
Median age in years (SD)		26.76 (7.55)		27.34 (6.60)	
Median BMI (SD)		51.00 (20.80)		56.00 (22.50)	
Tobacco Use Disorder (%)		3129 (11.14)		3486 (16.63)	
Antidepressant use (%)		16295 (58)		9063 (43.23)	
Psychiatric conditions (%)		8993 (32.01)		5043 (24.06)	
		Case	Control	Case	Control
AF	N (%)	2256 (8.03)	25838 (91.97)	3416 (16.30)	17547 (83.70)
	Median age (SD)	72.00 (12.62)	49.00 (20392)	69.00 (12.33)	53.00 (22.6)
CAD	N (%)	2881 (10.25)	25213 (97.1)	5487 (26.17)	15476 (73.83)
	Median age (SD)	68 (12.23)	49.00 (20.58)	68.00 (10.95)	50.00(22.84)
HF	N (%)	2514 (8.95)	25580 (91.05)	3183 (15.18)	17,780 (84.82)
	Median age (SD)	67.00 (18.03)	50.00 (20.53)	67.00 (16.65)	54.0 (22.61)

Supplementary Table 6. Sources of GWAS summary statistics used in PGS SNP weight estimation for UK Biobank and BioVU cohorts

Prediction cohort	Trait	Sample size	Ancestry	Reference
UK Biobank	AF	17931 cases and 115142 controls	Predominantly European	Christophersen et al. [1]
	BD	20352 cases and 31358 controls	European	Stahl et al. [2]
	CAD	60801 cases and 123504 controls	Predominantly European	Nikpay et al. [3]
	HF	40805 cases and 542362 controls	European	The full dataset (including UK Biobank individuals) is available in Shah et al. [4]). The dataset used in this study (with no UK Biobank individuals) is unpublished.
	MD	121198 cases and 329421 controls	European	The full dataset (including UK Biobank individuals) is available in Wray et al. [5]). The dataset used in this study (with no UK Biobank individuals) is unpublished.
	SCZ	40675 cases and 64643 controls	Predominantly European	Pardiñas et al. [6]
BioVU	BD	41917 cases and 371549 controls	European	Mullins et al. [7]
	MD	170756 cases and 329443 controls (excluding the 23andMe cohort)	European	Howard et al. [8]
	SCZ	53386 cases and 77258 controls	European	Trubetskoy et al. [9]

Supplementary Table 7. Prediction accuracy of PGSs generated for the UK Biobank cohort

Prediction cohort	PGS	Number of SNPs	N_{cases}	$N_{controls}$	OR per SD increase of PGS (95% CI)	p-value	Nagelkerke R^2
UK Biobank	AF	1002671	28634	316535	1.52 (1.5 - 1.54)	< 2E-16	0.030
	BD	1008170	1402	286162	2.01 (1.91 - 2.13)	< 2E-16	0.038
	CAD	1007431	24708	320461	1.59 (1.57 - 1.61)	< 2E-16	0.034
	HF	1006789	14142	330528	1.21 (1.18 - 1.23)	< 2E-16	0.0046
	MD	1007847	20090	286162	1.31 (1.29 - 1.33)	< 2E-16	0.011
	SCZ	987863	1387	286162	1.84 (1.74 - 1.94)	< 2E-16	0.028
BioVU	BD	778307	1694	47363	1.30 (1.23 - 1.37)	< 2E-16	0.0084
	MD	770389	8942	40115	1.16 (1.13 - 1.19)	< 2E-16	0.0053
	SCZ	779202	230	48827	1.57 (1.36 - 1.82)	4.6E-11	0.021

Supplementary Table 8. CVD incidence and average recruitment age of females who were baseline pre- and post-menopause in the UK Biobank (*** indicates a chi square p<2E-16 for comparison of CVD incidence between the two menopausal groups)

		Baseline pre-menopause		Baseline post-menopause		
		Case	Control	Case	Control	
AF	Count (%)	222 (0.8)	27076 (99.2)	6849 (6.1)	106288 (93.9)	***
	Average age at baseline in years (SD)	45.3 (2.5)	44.9 (2.6)	63.6 (4.6)	60.6 (5.4)	
CAD	Count (%)	185 (0.7)	27103 (99.3)	3288 (2.9)	109621 (97.1)	***
	Average age at baseline in years (SD)	45.4 (2.4)	44.9 (2.6)	62.9 (4.9)	60.7 (5.4)	
HF	Count (%)	130 (0.5)	27181 (99.5)	3510 (3.1)	110383 (96.9)	***
	Average age at baseline in years (SD)	45.3 (2.4)	44.9 (2.6)	63.7 (4.8)	60.7 (5.4)	

References

1. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE, Smith AV, Albert CM, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. *Nat Genet*. 2017;49:946-952.

2. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JRI, Gaspar HA, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet*. 2019;51:793-803.

3. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015;47:1121-1130.

4. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB, Morley MP, Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun*. 2020;11:163.

5. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet*. 2018;50:668-681.

6. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop S, Cameron D, Hamshere ML, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet*. 2018;50:381-389.

7. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, Als TD, Bigdeli TB, Børte S, Bryois J, et al. Genome-wide association study of more than 40,000 bipolar

disorder cases provides new insights into the underlying biology. *Nat Genet*. 2021;53:817-829.

8. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JRI, Hagenaars SP, Ward J, Wigmore EM, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci*. 2019;22:343-352.

9. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen C-Y, Dennison CA, Hall LS, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604:502-508.